Pharmaceutical industry news

What FDA's AI Warning Letter Tells Us About GMP Accountability

Opus Genetics aligns with FDA on Phase 3 trial for LCA5 therapy By Investing.com

Maharashtra FDA warns against three beauty creams after tests detect excessive mercury, lead levels

Vivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.

Opinion: San Diego helped invent biotech and must now fight to keep it

Biotech Alliance Ramps Up Drug Pricing Lobbying

Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios

Novartis to buy UK biotech Myricx Bio for up to $1.5B

Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™

Veraxa Biotech (VRXA) Stock Price, News & Analysis

NeuroSense joins ALS expert webinar on PrimeC and Phase 3 plans

Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment

Incyte pays $1.25B for Vega, adding a Phase 3 bleeding-disorder drug

VERAXA Biotech targets 2028 IND filing for lead candidate

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

FDA clears Vivos to test RadioGel in first U.S. cancer patients

Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for

Kingdom advances biotech ties at US convention

Inclusion of disadvantaged communities in public health research

U.S. Department of Health and Human Services and the U.S. Food and Drug Administration Commend DEA Action Against Certain Kratom-Related Substances, 7-OH Products

Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push

Startups move to Colorado amid concerns state losing its luster for tech companies

JAMP Chlorthalidone 12.5 mg tablet: Out of specification (Dissolution)

The dissolution may be out of specification in the affected lot.

Hotline IV Fluid Warmer System & Accessories

ICU Medical became aware of an increased likelihood of leakage in specific lots of L-70 Hotline Flui...

Opus Genetics aligns with FDA on Phase 3 trial for LCA5 therapy

Scribe notes down IPO ambition to fund lipid-lowering genetic meds through clinical trials

Trump Easing Testosterone Restrictions Sparks Health Warnings Over Radical Plan To Pump Up Men's Declining Hormone Levels

FDA accepts Pharvaris NDA for oral HAE attack treatment drug

Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London

Caris Life Sciences launches cancer blood test ‘Caris Detect’

Germany Modifies Healthcare Reforms to Ease Burden on Pharma

Opus Genetics aligns with FDA on Phase 3 trial for LCA5 therapy

VERAXA Biotech targets 2028 IND filing for lead candidate By Investing.com

VERAXA Biotech AG Provides Pipeline and Partnering Update, Advances BiTAC Development Strategy

Can-Fite BioPharma Announces Completion of Enrollment of First 247 Patients in Pivotal Phase 3 Piclidenoson Psoriasis Study Ahead of Interim Analysis

Belite Bio Announces Tinlarebant Phase 3 DRAGON Study Results to Be Presented at ISCEV 2026 and ASRS 2026 Meetings

Opus Genetics Reaches FDA Alignment on Phase 3 Design for OPGx-LCA5; BLA May Be Submitted Based on 6-Month Data

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Can-Fite (NYSE American: CANF) reaches key Phase 3 psoriasis interim analysis milestone

PEMGARDA faces 2027 EUA end as Invivyd talks next steps with FDA

FDA accepts Pharvaris NDA for oral HAE attack treatment drug By Investing.com

Ionis finishes key enrollment step for Angelman syndrome drug trial

Belite Bio takes Phase 3 Stargardt disease data to two eye meetings

Can-Fite’s psoriasis study reaches interim analysis after 247 patients enrolled

Opus Genetics clears FDA design for Phase 3 trial in childhood blindness

VERAXA says its BiTAC cancer pipeline is drawing partner interest

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

Pharvaris Announces FDA Acceptance of NDA for Deucrictibant IR Capsule for On-Demand Treatment of HAE Attacks

Pharvaris wins FDA review for oral HAE attack treatment

Swiss drugmaker Novartis buys UK biotech firm in $1.5bn deal

Maharashtra FDA tightens milk safety rules

Maharashtra FDA flags three beauty creams over toxic mercury and lead levels

NHS sets first-ever staff standards to tackle racism and violence

New NHS staff standards will make employers accountable for tackling racism, violence and sexual har...

AtaiBeckley Announces Last Patient Dosed in Phase 2b Elumina Trial of VLS-01 for Treatment-Resistant Depression; Topline Data Expected in Q4 2026

Novartis to acquire Myricx Bio in up to $1.5bn deal

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Should DayQuil be legal?